CD163 and neoplasm: For CD68+CD163− macrophages, we could not find consistent results, as the APBI 4C cohort suggests that a high infiltration of CD68+CD163− macrophages in the stromal compartment of tumor distant normal tissues improves 10-year DFS (p = 0.044), whereas the BBCC study suggests that a rather low prevalence of CD68+CD163− cells correlates with a better prognosis (p = 0.05).